RCS - Diaceutics PLC - Approval by CMS for enhanced data access

DiaceuticsAnnouncement

16/03/2022 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220316:nRSP8889Ea&default-theme=true

RNS Number : 8889E  Diaceutics PLC  16 March 2022

16 March 2022

 

Diaceutics PLC

("Diaceutics" or "the Company" or "the Group")

 

Diaceutics approved by Centers for Medicare & Medicaid Services for
enhanced data access

 

Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company,
announces it has been approved by the Centers for Medicare & Medicaid
Services (CMS) to receive US medical claims data at an increased frequency.
The data will be integrated with Diaceutics' weekly aggregated Lab data within
the DXRX diagnostic commercialisation platform, providing enhanced insight
into the testing landscape for Precision Medicine.

 

By increasing the frequency of data feeds, Diaceutics' pharma and diagnostic
clients can understand the evolving testing landscape in near real-time,
 empowering strategies to drive faster access to the right treatment. This is
particularly important when considering the profound impact of the COVID
pandemic on the testing for cancer and other diseases.

Diaceutics' data capabilities is one of the three key value drivers it has
integrated into its unique DXRX platform alongside its global Lab network and
product suite tailored for Precision testing.  Through its powerful data
analytics, machine learning and deep disease-level expertise and
understanding, Diaceutics transforms data into valuable and actionable
insights to build a comprehensive picture of a patient's diagnostic journey
and eliminate barriers to treatment.

Peter Keeling, CEO of Diaceutics commented, "The most competitive companies in
the diagnostic data space are those that not only can integrate very different
large data sets but can deliver near real time customer insights. We have been
working with the team at CMS for many years and this step up in data access
helps supercharge our service in the market. Reducing the lag time for receipt
of data will enable us to draw greater insight and value to help identify the
best possible testing journey sooner than is currently possible, meaning
treatment can be more timely and effective - a key goal for all involved in
Precision Medicine particularly in the wake of COVID's profound disruption to
testing for cancer and other rare diseases."

 

Enquiries:

 

 Diaceutics PLC
 Peter Keeling, Chief Executive Officer               Via Alma PR
 Philip White, Chief Financial Officer

 Stifel Nicolaus Europe Limited (Nomad & Broker)      Tel: +44 (0)20 7710 7600
 Ben Maddison
 Stewart Wallace
 Nick Adams

 Alma PR                                              Tel: +44(0)20 3405 0205
 Caroline Forde                                       diaceutics@almapr.co.uk
 Kieran Breheny
 Matthew Young

 

About Diaceutics

At Diaceutics we believe that every patient should have access to the right
treatment at the right time. We provide the world's leading pharmaceutical
companies with an end-to-end solution for the launch of precision medicine
diagnostics enabled by DXRX - The Diagnostic Network®.

 

DXRX is the world's first diagnostic commercialisation platform for precision
medicine, integrating multiple pipelines of real-world diagnostic testing data
from a global network of laboratories

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFLFLTVFIELIF